Efficiency in the biopharmaceutical space has never been more top-of-mind. The COVID-19 pandemic brought an unprecedented urgency to R&D and the key players delivered: Several groups produced a vaccine in record time. To maintain and improve on this...
2020 has been an eventful year: but 2021 will also require skilful navigation. Here's some of the people who are stepping up to leading roles as we head into a new year.
COVID-19 is like a big oak tree casting shade on all other biopharma industry developments. Vaccine-related articles dominate the most popular story rankings. With Pfizer and BioNTech now out in front in the coronavirus vaccine race, we track the related...
The gene therapy space is a rapidly developing areas in the industry, as a result those with expertise are finding their knowledge is invaluable to companies looking to advance in the space.
As we have entered the summer, companies have taken to refreshing their leadership positions, including at companies such as Gilead, Alnylam, and Maze Therapeutics.
BMS’ capture of Celgene caught much attention, due to the size and scale of the acqusition, but rival companies have taken the chance to snap up employees that have left after the deal.
As we enter spring, several companies have refreshed the look of their executive boards – some to strengthen their direction and some out of necessity.
While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.
In a significant move at the larger end of the biopharma world, AstraZeneca’s global VP of cardiovascular, renal and metabolism made the move to Novo Nordisk to head up its biopharm unit.
